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The expanding clinical challenge of respiratory tract infections due to resistant bacteria necessitates the
development of new forms of therapy. The development of a compound composed of silver coupled to a
methylated caffeine carrier (silver carbene complex 1 [SCC1]) that demonstrated in vitro efficacy against
bacteria, including drug-resistant organisms, isolated from patients with respiratory tract infections was
described previously. The findings of current in vitro studies now suggest that bactericidal concentrations of
SCC1 are not toxic to airway epithelial cells in primary culture. Thus, it was hypothesized that SCC1 could be
administered by the aerosolized route to concentrate delivery to the lung while minimizing systemic toxicity. In
vivo, aerosolized SCC1 delivered to mice resulted in mild aversion behavior, but it was otherwise well tolerated
and did not cause lung inflammation following administration over a 5-day period. The therapeutic efficacy of
SCC1 compared to that of water was shown in a 3-day prophylaxis protocol, in which mice infected with a
clinical strain of Pseudomonas aeruginosa had increased survival, decreased amounts of bacteria in the lung,
and a lower prevalence of bacteremia. Similarly, by using an airway infection model in which bacteria were
impacted in the airways by agarose beads, the administration of SCC1 was significantly superior to water in
decreasing the lung bacterial burden and the levels of bacteremia and markers of airway inflammation. These
observations indicate that aerosolized SCC1, a novel antimicrobial agent, warrants further study as a potential
therapy for bacterial respiratory tract infections.
can result in drug concentrations much higher than those that
can be achieved through intravenous administration and avoids
systemic exposure and toxicity (32). Nonetheless, inhaled antimicrobials are not routinely used for the treatment of acute pneumonia, in part due to the availability of effective systemic therapy
for the treatment of infections caused by sensitive organisms.
The emergence of multidrug-resistant organisms has rekindled an interest in inhaled antimicrobials as adjunct therapy,
especially in select populations with chronic lung disease and
in those with nosocomial hospital-acquired pneumonia and
ventilator-associated pneumonia (25). The delivery of tobramycin by inhalation is well established for the treatment of
Pseudomonas aeruginosa in patients with cystic fibrosis (CF)
lung disease (32) and is also used to treat non-CF patients (11).
The organisms responsible for nosocomial pneumonias vary,
but they commonly include resistant strains of Pseudomonas
and methicillin (meticillin)-resistant strains of Staphylococcus
aureus (22). These pathogens are also found to be the causes of
other diseases that are marked by persistent airways infections,
such as non-CF bronchiectasis and chronic obstructive pulmonary disease (21, 30). Thus, novel antimicrobials that are active
against these strains of resistant organisms and that can be
delivered by the inhalation route are likely to have utility for
the treatment of a broad range of patient populations.
Silver is an antimicrobial agent that is attractive as a potential therapy for respiratory tract infections. The broad-spectrum antimicrobial effects of silver have been appreciated for
centuries (35). Although the medicinal use of silver waned

Respiratory tract infections are a major cause of morbidity
and mortality worldwide (8). This trend has been exacerbated
by drug-resistant bacterial strains that are rapidly increasing in
community-acquired as well as hospital-acquired infections.
Moreover, hospital-acquired pneumonia and ventilator-associated pneumonia are the leading causes of death from nosocomial infections and affect up to 25% of all intensive care unit
patients, with mortality rates being as high as 70% (4).
Accordingly, the therapy currently recommended for hospitalized patients with pneumonia includes broad-spectrum
antibiotics active against organisms with multidrug resistance (2). Furthermore, these serious pulmonary infections
require the systemic delivery of high doses of antibiotics to
overcome not only the potential resistance of the infecting
organisms but also the low level of lung tissue penetration of
many agents. A more attractive alternative for the treatment of
infections caused by these resistant organisms, as well as organisms sensitive to antimicrobials delivered through the typical oral and intravenous routes, is the aerosol route of drug
delivery, which is uniquely possible for respiratory tract infections. The deposition of drug in the lungs via the inhaled route
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after the advent of antibiotics, silver-containing products and
compounds, such as silver nitrate, silver sulfadiazine, and silver-impregnated bandages, continue to be used for the treatment of burns and wounds (24) and are particularly effective
against difficult-to-treat bacteria, such as P. aeruginosa. More
recently, silver-impregnated catheters and endotracheal tubes
have been developed to decrease the likelihood of catheterassociated, hospital-acquired infections and ventilator-associated pneumonia, respectively, and are currently under investigation (7, 34). Despite the encouraging results obtained in
studies of silver-impregnated devices, no silver-based antimicrobials have been developed for direct delivery to the lung.
To achieve clinical utility, a nebulized silver compound must
have demonstrated efficacy against respiratory pathogens without toxicity to the host. The toxicity of silver used in clinical
materials is reported to be minimal, with the notable rare
cosmetic side effect of gray skin known as argyria (23). The
toxicity of silver compounds, however, can often be linked to
the carrier molecules (13). Consequently, the rational design of
a new silver-based antimicrobial must ideally include coordination of the use of the bioactive metal with a nontoxic carrier.
We have previously reported the synthesis and in vitro antimicrobial properties of the N-heterocyclic carbene silver complex
designated SCC1, for silver carbene complex 1, formed from
the coupling of silver to the xanthine derivative, methylated
caffeine (20). Xanthine derivatives have been used for multiple
purposes, including bronchodilation. Caffeine (Fig. 1A) is
readily available and has low toxicity, properties which are
attractive as a carrier for the delivery of silver to the lung (3).
Thus, SCC1 appears to have properties ideal for use as a
nebulized antimicrobial. To begin to assess the suitability of
SCC1 as a nebulized antimicrobial, the in vitro cytotoxicity of
SCC1 in airway epithelial cells in primary culture and in vivo
efficacy of SCC1 in mouse models have been examined.
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FIG. 1. Structures of caffeine (A), methylated caffeine used as a
carrier in SCC1 (B), and the methylated caffeine silver acetate designated SCC1 (C).

Drugs. The silver carbene complex designated SCC1 (Fig. 1C) is composed of
silver complexed to a methylated caffeine carrier (Fig. 1B) (20). SCC1 and the
methylated caffeine SCC1 precursor (Fig. 1B) were both reconstituted in water
(Milli-Q synthesis system; Millipore Corp., Billerica, MA) to a concentration of
10 mg/ml (Ksp of SCC1, 11 mg/ml) and stored at ⫺80°C until use.
Mice. Male C57BL/6J mice (age, 8 to 10 weeks; Jackson Laboratories, Bar
Harbor, ME) were used for these studies, which were approved by the Washington University School of Medicine (St. Louis, MO) Animal Studies Committee. The animals were housed in a barrier facility under pathogen-free conditions
until they were inoculated with bacteria.
Bacteria. A mucoid clinical isolate of P. aeruginosa designated PA M57-15 was
provided by Thomas Ferkol (Washington University). For the infection model
experiments, bacteria were streaked from frozen stocks onto tryptic soy agar
(TSA) and incubated overnight at 37°C. Cells from the fresh plates were suspended in Luria broth (LB) to an optical density at 650 nm (OD650) of 0.2 and
grown at 37°C in a shaking incubator at 200 rpm to an OD650 of 0.4, which
corresponds to ⬃2 ⫻ 108 CFU/ml for P. aeruginosa, as confirmed by the plating
of serial dilutions.
mTEC cultures. Highly differentiated mouse tracheal epithelial cell (mTEC)
cultures were established by using air-liquid interface conditions, as described
previously (37). Briefly, cells were harvested from the tracheas by pronase digestion, and epithelial cells were selected from fibroblasts by differential adherence. To initiate the cultures, cells were seeded on supported membranes (Transwell; Costar-Corning, Corning, NY) and proliferated in growth factor-enriched
medium maintained in the upper and lower chambers until the cell layer was
confluent and sufficient to exclude medium from leaking into the apical compartment. The air-liquid interface condition was then created for the induction of
cell differentiation by aspirating the medium from the apical chamber and providing fresh medium to the lower chamber every 3 days. The cells used in these
studies were cultured under these conditions for at least 7 days, at which time
ciliated (approximately 30% to 50%) secretory and basal cells were present.
In vitro cytotoxicity studies. Concentrations of SCC1 ranging from 0 to 500
g/ml (0, 5, 10, 50, 100, 200, 300, 400, and 500 g/ml) were applied to the apical
surface of mTEC cultures, and the cultures were allowed to incubate for 24 h.
Subsequently, the cells on the Transwell membranes were rinsed with phosphatebuffered saline (PBS) and fixed with 4% paraformaldehyde in PBS, pH 7.4, for
10 min at 25°C. The membranes containing the cells were mounted on glass
slides by use of a medium that contains 4⬘,6-diamidino-2-phenylindole (DAPI) to
stain intracellular DNA (Vectashield; Vector Laboratories, Burlingame, CA).
Microscopy was performed with a epifluorescent microscope (DM5000; Leica,
Wetzlar, Germany) with a Retiga 200R charge-coupled-device camera (Q-Imaging, Surrey, British Columbia, Canada) interfaced with Q-Capture Pro software (Q-Imaging). Cell enumeration was performed by counting the number of
DAPI-stained nuclei per high-power field in at least three fields per well of cells.
Each SCC1 concentration was applied to at least two wells of the mTEC cultures.
The average number of nuclei per high-power field in the wells that were not
treated with SCC1 served as the control against which the number of cells in the
treated wells were normalized, as follows: percent surviving cells ⫽ (average
number of nuclei in treated wells/average number of nuclei in untreated wells) ⫻
100%. Data are presented as the averages and standard deviations (SDs) of the
normalized cell numbers.
Mouse toxicity studies. Two groups of five mice each were placed in a multidosing animal chamber (Buxco Research Systems, Wilmington, NC). After
accommodation to the chamber for 5 min, the animals were exposed for 5 min
to 0.5 ml of nebulized water or SCC1 dissolved in water at a concentration of 10
mg/ml. Both SCC1 and water were delivered via an Aeroneb Lab apparatus
(Aerogen Inc., Galway, Ireland) connected directly through the lid of the multidosing chamber. The Aeroneb Lab nebulizer is based on micropump technology that produces fine particles (1 to 5 m) in a low-velocity aerosol (26). The
treatment with either nebulized SCC1 or water was repeated twice daily for a
total of 5 days. The mice were weighed daily and were monitored during the
exposure periods for activity, including their location in the multidosing chamber
relative to the location of the nebulizer and grooming or jumping behaviors. On
the last day of treatment, the mice were placed in the chamber and photographed
from an aerial view prior to treatment and every 15 s beginning 5 s after the onset
of aerosol production. Their position within the chamber was then plotted
relative to the position of nebulizer. At the end of the 5-day exposure period, the
mice were euthanized and the lungs were collected for histological examination.
The experiment was repeated with similar groups of mice.
Prophylaxis protocol. Evaluation of the efficacy of SCC1 by using both the
acute and agarose bead infection models employed identical prophylaxis proto-
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FIG. 2. In vitro cytotoxicity of SCC1. SCC1 was applied to the
apical surface of primary cultured, differentiated mTECs for 24 h,
followed by quantification of the cell number to determine cytotoxicity.
The number of cells surviving at each treatment concentration was
compared to the number of cells in control medium-treated samples.
The results are the means ⫾ SDs of the percent surviving cells in
replicate images of low-power fields and are representative of the
results of at least two independent experiments.

were treated according to the prophylaxis protocol. At 72 h after infection, the
mice were euthanized, the BAL fluid specimens were obtained and analyzed as
described for the acute infection model, the spleens were harvested for qualitative bacteriology, and the lungs were harvested for histology (two mice per
group) and quantitative bacteriology (two mice per group). The results of two
separate experiments were pooled, for total results for eight mice per group,
except for the one mouse that died during anesthesia.
Histology. The lungs were inflation fixed under 20 cm of water in situ via the
intratracheal instillation of 2% paraformaldehyde and were then embedded in
paraffin blocks. Sections (5 m) were mounted on slides and stained with hematoxylin-eosin. Microscopy images were acquired by the use of Axiovision
(version 3.1) software (Carl Zeiss, Thornwood, NY).
Statistical analysis. All analyses were performed with the Prism (version 4)
program (GraphPad Software, San Diego, CA). The in vitro cytotoxicities of
multiple doses of SCC1, as well as in vivo aversion data, were compared by
analysis of variance and post hoc analysis to determine statistical differences. The
in vivo survival curves in the acute infection model were compared by a log-rank
test. Changes in animal weights in the acute and agarose bead infection models,
the lung bacterial burden in the acute infection model, and cytokine concentrations were compared by independent groups t tests. In the agarose bead model,
bacterial clearance was measured as a categorical variable and the groups were
compared by Fisher’s exact test of a contingency table (the number of animals
with bacteria in the lungs versus the number of animals that cleared the bacteria).
Similarly, the levels of bacteremia in SCC1- and water-treated animals were
compared by Fisher’s exact test of the corresponding contingency table.

RESULTS
In vitro cytotoxicity of SCC1. Prior to in vivo testing, the in
vitro margin of safety of SCC1 was assessed. Following exposure to concentrations of SCC1 that included the MIC and
minimum bactericidal concentration of P. aeruginosa PA
M57-15 (2 and 4 g/ml, respectively), cell numbers were determined in a primary cell culture model of the respiratory
epithelium. The cell numbers remained unchanged at concentrations corresponding to the MIC90 of SCC1, but cytotoxicity
was significant by the time that a concentration of 200 g/ml
was tested (Fig. 2). As determined by curve fitting of the
semilogarithmically transformed data, the 50% lethal dose of
SCC1 in this model is 289 g/ml, which is 48-fold greater than
the MIC90 for all of the P. aeruginosa strains previously tested
and 145-fold above the MIC for PA M57-15 (20).
Effect of nebulized SCC1 solution on mouse activity and
lung inflammation. As an initial in vivo evaluation of the suit-
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cols. The mice were pretreated with either 0.5 ml of nebulized water as a control
or 0.5 ml of SCC1 at a concentration of 10 mg/ml. The mice were then immediately anesthetized intraperitoneally with 2.5% tribromoethanol (Avertin) at a
dose of 0.015 ml/g of mouse body weight. The tracheae were exposed by dissection and then cannulated with a 22-gauge angiocatheter through which 50 l of
P. aeruginosa strain PA M57-15 grown as described above was injected into the
airways. The first dose and inoculation were completed within 30 min and
together were considered to be time zero in the experiment. Subsequent doses
were administered according to the following schedule: doses 2 and 3 at 4 and
8 h, respectively; doses 4, 5, and 6 at 24, 28, and 32 h, respectively; and doses 7,
8, and 9 at 48, 52, and 56 h, respectively. The mice were evaluated at 72 h after
dose 1 and inoculation (see Fig. 4).
Acute infection model. The acute infection model was used to mimic the
pathology seen in acute bacterial pneumonia. Following administration of the
pretreatment dose of either SCC1 or water, groups of mice were anesthetized
intraperitoneally with 2.5% tribromoethanol at a dose of 0.015 ml/g of mouse. P.
aeruginosa strain PA M57-15 was delivered to each mouse intratracheally, as
described above. The dose ranged from 2.5 ⫻ 106 to 3.25 ⫻ 107 CFU per mouse
in each of five separate experiments with about five mice per treatment group.
The data from these experiments were pooled so that data for a total of 25 mice
were included in the SCC1 treatment group and data for 26 mice were included
in the water control group. Mice were weighed daily and were treated three times
daily by using the prophylaxis protocol. The surviving mice were then euthanized
on day 3 by carbon dioxide inhalation. Bronchoalveolar lavage (BAL) fluid
samples were obtained as described previously and separated (4,000 ⫻ g, 10 min,
4°C) into cell-free supernatants and cells (36). The cell pellets from the BAL
fluid were used for white blood cell total and differential cell counts, and the
supernatants were frozen for cytokine analysis. Total white blood cell counts
were determined on a Hemavet 950 apparatus (Drew Scientific, Oxford, CT).
Differentials were performed by staining the cells with Diff-Quick (Hema 3
manual staining system; Fisher Scientific), followed by microscopy. The BAL
fluid was analyzed for the cytokines MIP-2 and KC by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). The lungs were harvested
for quantitative bacteriology as described previously (36). The spleens were
homogenized in 1 ml of PBS solution (PowerGen 125 homogenizer; Fischer
Scientific), and 10 l of the homogenate was placed on a TSA plate overnight at
37°C. The presence or the absence of bacterial colonies was noted to determine
bacteremia. The lower level of detection for both lung and spleen homogenates
by this technique is 102 CFU/ml. One of the set of lung plates (see Fig. 4C) and
three sets of plates of spleen homogenates (see Fig. 4D) were eliminated from
the analysis because they appeared to be contaminated.
Time course of treatment effects in acute infection model. To investigate the
efficacy of SCC1 on a day-to-day basis, a cohort of 24 mice was subjected to the
prophylaxis protocol, with 12 mice receiving nebulized doses of SCC1 (5 mg per
dose) and the other 12 mice receiving water. All mice were infected with 3 ⫻ 106
CFU per mouse of PA M57-15, according to the acute infection model. However,
as treatment proceeded, a group of mice (n ⫽ 4) was evaluated daily to monitor
the mice for changes in lung bacterial burden; the influx of leukocytes, as
determined by evaluation of BAL fluid; and bacteremia. On days 1 and 2, the
lungs of one animal from each group were harvested for histological examination, and the lungs from the remaining three mice were harvested to determine
the lung bacterial burden. Because two animals in the water-treated group died
between days 2 and 3, the lungs of all of the remaining mice were harvested for
quantitative bacteriology but lungs of none of the mice were evaluated for
histology.
Agarose bead model. The agarose bead model of chronic P. aeruginosa infection was used to achieve an airway infection that mimics that seen in patients with
CF (36). To produce the bacterium-laden beads, a sterile flask with a 2% agarose
gel was melted, equilibrated to 55°C, and mixed with P. aeruginosa strain PA
M57-15 grown in tryptic soy broth. An aliquot of the infected agarose was quickly
added to a beaker of rapidly stirring mineral oil and then gradually cooled. The
beads were next washed once in a separatory funnel with warm 0.5% sodium
deoxycholate, then once in warm 0.25% sodium deoxycholate, and finally, four
times in sterile PBS solution. The beads were cultured on a TSA plate to
determine the bacterial load, and the concentrated slurry was stored overnight at
4°C. On the following morning, the numbers of CFU were counted and the bead
bacterial load was calculated. The bead slurry was diluted with PBS (typically 2:5
or 3:5) to obtain the desired dose of bacteria in a 50-l aliquot. A cohort of eight
mice was pretreated with either SCC1 (n ⫽ 4) or water (n ⫽ 4). Subsequently, the
mice were anesthetized with 2.5% tribromoethanol, and the tracheae were exposed by cutdown and cannulated with a 22-gauge angiocatheter, followed by
intratracheal instillation of the aliquot of P. aeruginosa PA M57-15-impregnated
agarose beads (dose, 3 ⫻ 105 CFU per mouse). The mice were weighed daily and
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ability of SCC1 as a nebulized therapy, mice were placed in a
multidosing chamber and observed during their exposure to
aerosolized water or SCC1 twice daily over a 5-day period. The
animals that were exposed to water approached the nebulizer
(Fig. 3B; time, 5 s) and then moved to the opposite side of the
chamber in the direction of the leading edge of the mist cloud
(Fig. 3B; times, 20 s and 35 s). Once the concentration
throughout the dosing chamber equilibrated, as indicated by
diffusion of the mist cloud, the mice dispersed throughout the
chamber. In contrast, animals exposed to SCC1 immediately
moved away from the mist and congregated at the opposite
end of the dosing chamber (Fig. 3A and B; time, 5 s), although
they subsequently dispersed after the chamber filled with mist
(Fig. 3B; time, ⬎35 s). To determine the portion of the SCC1
molecule that was aversive, animals previously exposed to nebulized water were exposed to the nebulized methylated caffeine
carrier (Fig. 1B). Even though these animals had previously
approached the water mist, they moved to the opposite side of
the chamber following initiation of the carrier compound aerosol, although not as quickly as the naïve animals when they
were exposed to SCC1 itself (Fig. 3B). Notably, the animals
exhibited no weight loss or changes in grooming or jumping
behaviors after repeated dosing of nebulized water or SCC1 (5
mg/dose SCC1, 5 min exposure, twice daily) over a period of 5
days (data not shown). After the 5-day treatment period, the
lungs were harvested for histologic evaluation. The lungs from
both water- and SCC1-treated mice appeared to be histologically normal. Specifically, the lungs from the SCC1-treated
animals did not show evidence of increased immune cell infiltration (Fig. 3C). Accordingly, we next tested the efficacy of
SCC1 for the treatment of lung infections in two different
mouse models, an acute pneumonia model and a chronic airway infection model.
Effect of nebulized SCC1 on survival, bacterial lung burden,
and dissemination following acute in vivo infection. Mice were
given a single prophylactic dose of nebulized SCC1 and were
then intratracheally infected with P. aeruginosa; this procedure
was followed by the administration of eight additional doses of
SCC1 over the next 72 h (Fig. 4A). Mice that received SCC1

according to this protocol had improved survival compared to
that of mice that received treatment with the vehicle control,
water (Fig. 4B). Of the SCC1-treated animals, 22 of 25 survived (88%), whereas 16 of 26 water-treated mice survived
(62%), for a 26% survival advantage in this model (P ⫽ 0.04).
Death in the water-treated mice occurred especially at 48 h
postinfection. At 72 h, no statistically significant difference in
weight change was noted between the groups (data not shown).
Analysis of the lung bacterial burden in the surviving mice after
72 h showed a distinct difference between treatment groups
characterized by a total absence of bacteria in the lungs of
more than half of the SCC1-treated survivors (12 of 21 [57%];
one set of plates appeared to be contaminated with a species
other than Pseudomonas, and those plates were eliminated
from the analysis). In contrast, the lungs of all surviving mice
treated with water had greater than 105 CFU/lung (Fig. 4C;
water-treated mice [n ⫽ 16], 2.7 ⫻ 107 ⫾ 0.9 ⫻ 107 CFU/lung;
SCC1-treated mice [n ⫽ 21], 2.9 ⫻ 106 ⫾ 2.0 ⫻ 106 CFU/lung;
P ⫽ 0.004). Furthermore, there was a significant increase in the
number of water-treated mice from which bacteria were recovered from the spleen compared to the number in the SCC1treated group (Fig. 4D; water-treated group, 9 of 13 mice
[three sets of spleens appeared to grow a species other than
Pseudomonas and were eliminated from the analysis]; SCC1treated group, 4 of 22 mice; P ⫽ 0.002). For the majority of the
SCC1-treated mice (82%), bacteria could not be cultured from
the spleen.
Effect of nebulized SCC1 on serial changes in inflammation,
bacterial lung burden, and dissemination following acute in
vivo infection. To investigate the efficacy of SCC1 on a day-today basis in the acute infection model, 24 mice were infected
with 3 ⫻ 106 CFU per mouse of strain PA M57-15 and subjected to the prophylaxis protocol (Fig. 4A), with half of the
mice receiving nebulized doses of SCC1 and the other half
receiving water. As treatment proceeded, a group of mice (n ⫽
3 to 4) from each treatment group was evaluated daily to
monitor changes in the lung bacterial burden, the influx of
leukocytes as determined by BAL, and bacteremia. Animals in
both treatment groups lost weight at the same rate until day 3,
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FIG. 3. Effect of nebulized SCC1 solution on mouse position relative to aerosol source and on lung inflammation. Mice were exposed to
aerosolized water or SCC1 twice daily for 5 days in a multidosing chamber designed with a nebulizer (neb) at one end. (A) Representation of the
location of mice obtained 5 s after the initiation of an SCC1 aerosol treatment. (B) Means ⫾ standard errors of mouse position relative to that
of the nebulizer device at the indicated times after the initiation of nebulization. *, P ⬍ 0.01, SCC1 versus water. (C) Representative lung sections
from water- and SCC1-treated mice after day 5 of treatment. The sections were stained with hematoxylin-eosin. Bar, 100 m.
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when the SCC1-treated animals began to gain weight (data not
shown). After 24 h, the bacterial burden in the lungs were
similar in the water- and SCC1-treated groups (water-treated
group [n ⫽ 3], 0.41 ⫻ 106 ⫾ 0.1 ⫻ 106 CFU/lung; SCC1-treated
group [n ⫽ 3], 1.9 ⫻ 106 ⫾ 1.7 ⫻ 106 CFU/lung; P ⫽ 0.42). By
the second day of treatment with SCC1, the lungs of the mice
had 100-fold less bacteria than the lungs of the water-treated
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FIG. 5. Effects of nebulized SCC1 on serial changes in bacterial
lung burden and dissemination following acute in vivo infection. A
cohort of 24 mice was subjected to the prophylaxis protocol described
in the legend to Fig. 4A; however, a group of four mice in each
treatment group was evaluated daily (three mice for quantitative bacteriology, one mouse for histology). (A) Concentration of bacteria
recovered from the lungs of mice evaluated at 24, 48, and 72 h after
inoculation. Bars, mean concentrations; *, P ⫽ 0.005. Mice that died
between 48 and 72 h are represented by an X and were not analyzed.
(B) Bacteremia as determined by the recovery of bacteria from the
spleens of mice evaluated at 24, 48, and 72 h. *, P ⫽ 0.01.

mice (Fig. 5A; water-treated group [n ⫽ 3], 1.2 ⫻ 107 ⫾ 0.4 ⫻
107 CFU/lung; SCC1-treated group [n ⫽ 3], 7.3 ⫻ 104 ⫾ 5.8 ⫻
104 CFU/lung; P ⫽ 0.04). By day 3, the difference was 1,000fold (water-treated group [n ⫽ 2], 8.5 ⫻ 107 ⫾ 4.9 ⫻ 107
CFU/lung; SCC1-treated group [n ⫽ 4], 5.0 ⫻ 104 ⫾ 4.0 ⫻ 104
CFU/lung; P ⫽ 0.005). Two of the animals in the water-treated
group died overnight on day 2 before their lungs could be
assayed. Thus, the difference in the lung bacterial burdens is
likely underestimated. By day 3, all of the surviving animals in
the water-treated group but none of the SCC1-treated animals
had bacteria in their spleens (Fig. 5B; day 3, n ⫽ 4 in each
group; P ⫽ 0.01, contingency table). Thus, consistent with the
changes in survival noted after day 2, SCC1 treatment resulted
in the clearance of bacteria from the lungs and the prevention
of bacteremia between days 2 and 3.

Downloaded from http://aac.asm.org/ on March 8, 2014 by Washington University in St. Louis

FIG. 4. Effects of nebulized SCC1 on survival, bacterial lung burden, and bacterial dissemination following acute in vivo infection.
(A) Prophylaxis protocol. Mice received pretreatment with water or
SCC1, were infected intratracheally with P. aeruginosa PA M57-15, and
were then treated twice more with SCC1. Three treatments per day
were administered on the following 2 days, prior to evaluation at 72 h
after inoculation. (B) Kaplan-Meier survival curves showing the rate of
survival of SCC1-treated mice (22/25 [88%]) versus that of mice
treated with water (16/26 [62%]). *, P ⫽ 0.04. (C) Concentration of
bacteria recovered from the lungs of mice surviving at 72 h. Bars, mean
concentrations; *, P ⫽ 0.004. (D) Bacteremia as determined by recovery of bacteria from the spleen after the indicated treatment in surviving mice analyzed at 72 h. *, P ⫽ 0.002.
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Effect of nebulized SCC1 on P. aeruginosa-induced inflammation in the acute lung infection model. The inflammatory
response in the lungs of mice treated with water or SCC1 72 h
after the initial infection was next examined. Lung tissue sections showed regional variation in pneumonitis, with the affected areas demonstrating perivascular, peribronchiolar, and
alveolar accumulation of immune cells. By taking these features into account, the range of inflammation between the
water- and SCC1-treated groups was increased in the lungs of
the water-treated animals compared to that in the lungs of the

SCC1-treated animals (Fig. 6A). Neither the total leukocyte
counts nor the neutrophil counts recovered from BAL fluid,
however, were different (Fig. 6B and C; for total leukocytes,
3.4 ⫻ 106 ⫾ 0.5 ⫻ 106 in the water-treated group [n ⫽ 16],
3.1 ⫻ 106 ⫾ 0.3 ⫻ 106 in the SCC1-treated group [n ⫽ 22] [P ⫽
0.64]; for neutrophils, 3.3 ⫻ 106 ⫾ 0.5 ⫻ 106 in the watertreated group [n ⫽ 16] and 2.7 ⫻ 106 ⫾ 0.3 ⫻ 106 in the
SCC1-treated group [n ⫽ 22] [P ⫽ 0.37]). The numbers of
macrophages recovered in BAL fluid were statistically significantly higher in the SCC1-treated mice than the water-treated
mice (Fig. 6D; water-treated group [n ⫽ 16], 1.0 ⫻ 105 ⫾ 0.2 ⫻
105; SCC1-treated group [n ⫽ 22], 2.2 ⫻ 105 ⫾ 0.4 ⫻ 105; P ⫽
0.02). In the mouse, MIP-2 and KC are neutrophil chemoattractants homologous to human interleukin-8. While the concentration of MIP-2 was lower in the SCC1-treated mice (Fig.
6E; water-treated group [n ⫽ 16], 1.1 ⫾ 0.5 ng/ml; SCC1treated group [n ⫽ 22], 0.12 ⫾ 0.02 ng/ml; P ⫽ 0.02), both
treatment groups had similar levels of KC in their BAL fluid
(Fig. 6F; water-treated group [n ⫽ 16], 1.8 ⫻ 10⫺1 ⫾ 0.4 ⫻
10⫺1 ng/ml; SCC1-treated group [n ⫽ 22], 1.1 ⫻ 10⫺1 ⫾ 0.3 ⫻
10⫺1 ng/ml; P ⫽ 0.10). Importantly, these samples were obtained from the mice that survived for 72 h and did not include
samples from the animals that died at 48 h.
Effect of nebulized SCC1 on P. aeruginosa in the agarose
bead infection model. The effect of SCC1 was evaluated in a
model of airway infection, the agarose bead infection model, to
compare the effects of SCC1 in this model to those seen in the
acute infection model. Unlike the acute infection model that
allows for alveolar deposition of bacteria more typical of pneumonia, the agarose bead infection model restricts bacteria primarily to the medium and small airways sparing the alveoli
(Fig. 4). In contrast to the acute lung infection model, no
animals died during the 72-h observation period, and the
SCC1-treated mice in this model lost significantly less weight
than the water-treated mice (Fig. 7A; water-treated animals
[n ⫽ 7], ⫺16 ⫾ 3; SCC1-treated animals [n ⫽ 8], ⫺4 ⫾ 2; P ⫽
0.008). Importantly, the burden of bacteria in the lung was also
significantly reduced by SCC1 treatment, such that all of the
SCC1-treated animals cleared their infections (Fig. 7B; watertreated group [n ⫽ 3], 3.1 ⫻ 106 ⫾ 5.0 ⫻ 106 CFU/lung;
SCC1-treated group [n ⫽ 4], 0 CFU/lung; P ⫽ 0.03, contingency table; the lungs of the remaining animals were examined
histologically). Similar to the findings from the acute infection
model, the clearance of pulmonary bacteria was associated
with the clearance of bacteremia. All of the water-treated
animals exhibited bacteremia, whereas bacteria were recovered from the spleens of none of the SCC1-treated animals
(Fig. 7C; water-treated group, n ⫽ 7; SCC1-treated group, n ⫽
8; P ⫽ 0.0002, contingency table).
Effects of nebulized SCC1 on P. aeruginosa-induced lung
inflammation in the agarose bead infection model. Similar to
the findings from the acute lung infection model, lung tissue
sections in the agarose bead model of chronic airway infection
at 72 h showed regional variations in inflammatory infiltrates.
The delivery of sterile beads to the lungs of untreated animals
resulted in little or no inflammation (data not shown). However, the level of inflammation was marked in the watertreated animals infected with P. aeruginosa and especially occurred in regions marked by the anatomic location of the
bacteria-laden beads (Fig. 8A, top panel). The lungs of the

Downloaded from http://aac.asm.org/ on March 8, 2014 by Washington University in St. Louis

FIG. 6. Effect of nebulized SCC1 on lung inflammatory cells and
cytokine expression following acute in vivo infection. The lungs from
mice treated as described in the legend to Fig. 4A were analyzed.
(A) Representative images of lung sections depicting the range in
intensity of inflammation (low to high) observed in the lungs of mice
treated with water or SCC1 after infection with P. aeruginosa. Sections
were stained with hematoxylin-eosin. Bar, 400 m. Mice underwent
BAL at 72 h after infection with P. aeruginosa. (B) Total inflammatory
cell numbers are depicted: leukocytes (WBC) (B), neutrophils (polymorphonuclear leukocytes [PMN]) (C), and macrophages (M⌽; *, P ⫽
0.02) (D). Also shown are the results for the chemokines MIP-2 (*,
P ⫽ 0.02) (E) and KC (F). Shown are the means ⫾ SDs for four
samples.
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FIG. 7. Effect of nebulized SCC1 in the agarose bead infection
model. Mice were treated with water or SCC1 as described in the
legend to Fig. 4A before and after infection with P. aeruginosa PA
M57-15-laden agarose beads. (A) Weight change. Bars, mean percent
change from the initial body weight; *, P ⫽ 0.008. (B) Concentration
of bacteria recovered from the lungs of mice surviving at 72 h after
inoculation. Bars, mean concentrations; *, P ⫽ 0.03. (C) Bacteremia
determined by recovery of bacteria from the spleen after the indicated
treatment in surviving mice at 72 h. *, P ⫽ 0.0002.

DISCUSSION
As reported previously, the silver-caffeine compound designated SCC1 was effective for the inhibition of the in vitro
growth of numerous respiratory pathogens, including strains of
Pseudomonas aeruginosa and multidrug-resistant organisms
from the Burkholderia cepacia complex for which the MIC90

FIG. 8. Effects of nebulized SCC1 on lung inflammation in the agarose bead infection model. The lungs from mice infected with agarose beads
impregnated with PA M57-15 and treated as described in the legend to Fig. 7 were analyzed. (A) Representative images of the lungs of mice treated
with nebulized water or SCC1 after infection with PA M57-15-laden agarose beads. Blue asterisks, peripheral airways containing beads. Bar, 400
m. Mice underwent BAL at 72 h after infection with PA M57-15-laden agarose beads. Total inflammatory cell numbers are depicted: leukocytes
(WBC; *, P ⫽ 0.02) (B); neutrophils (polymorphonuclear leukocytes [PMN]; *, P ⫽ 0.01) (C); and macrophages (M⌽) (D). Also shown are the
results for the chemokines MIP-2 (*, P ⫽ 0.04) (E) and KC (*, P ⫽ 0.007) (F). Shown are the means ⫾ SDs for four samples.
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SCC1-treated animals had minimal inflammation that was primarily localized in a peribronchiolar distribution surrounding
airways that contained beads (Fig. 8A, lower panel). The majority of the lungs from the SCC1-treated animals exhibited
little evidence of infection. This difference in airway inflammation was reflected in the BAL fluid from water- and SCC1treated animals; the total leukocyte and neutrophil counts recovered from the SCC1-treated animals were significantly
reduced (Fig. 8B and C; for total leukocytes, 2.1 ⫻ 105 ⫾ 0.7 ⫻
105 in the water-treated group [n ⫽ 7] and 3.2 ⫻ 104 ⫾ 0.8 ⫻
104 in the SCC1-treated group [n ⫽ 8] [P ⫽ 0.02]; for neutrophils, 1.7 ⫻ 105 ⫾ 0.6 ⫻ 105 for the water-treated group [n ⫽
7] and 6.0 ⫻ 103 ⫾ 3.0 ⫻ 103 for the SCC1-treated group [n ⫽
8] [P ⫽ 0.01]). The number of macrophages recovered was less
for the SCC1-treated animals, but the number was not statistically different from that recovered from the water-treated
mice (Fig. 8D; water-treated group [n ⫽ 7], 3.9 ⫻ 104 ⫾ 1.1 ⫻
104; SCC1-treated group [n ⫽ 8], 2.6 ⫻ 104 ⫾ 0.8 ⫻ 104; P ⫽
0.3). The concentrations of the mouse neutrophil chemoattractants MIP-2 and KC were both dramatically reduced in the
SCC1-treated animals; the concentration of KC was below the
level of detection in all SCC1-treated animals (Fig. 8E and F;
for MIP-2, 0.78 ⫾ 0.6 ng/ml in the water-treated group [n ⫽ 7]
and 0.011 ⫾ 0.001 ng/ml in the SCC1-treated group [n ⫽ 8]
[P ⫽ 0.04, contingency table]; for KC, 0.077 ⫾ 0.07 ng/ml in the
water-treated group [n ⫽ 7] and no KC detected in the SCC1treated group [n ⫽ 8] [P ⫽ 0.007, contingency table]).
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g/ml (20), and the 50% lethal dose for respiratory epithelial
cells treated with SCC1, 289 g/ml, this compound appears to
have a very low level of toxicity at the doses delivered. This
conclusion is supported by the findings of the in vivo studies,
which showed that the administration of SCC1 by nebulization
to mice results in no toxic effects, other than a mild aversion to
the methylated caffeine carrier.
The efficacy of SCC1 was tested in two specific lung infection
protocols that were developed to model two types of disease
that might be treated with aerosolized SCC1. The infection
achieved by the direct intratracheal instillation of motile bacteria models acute pneumonia in humans, while the instillation
of bacteria-laden beads models the chronic infection of the
airways seen in bronchiectasis CF patients and non-CF patients. This agarose bead infection model has features similar
to the features of clinical infections in patients with CF,
namely, obstruction of small airways with bacteria-laden material and the restriction of inflammation primarily to the peribronchial areas (27). More representative of the human disease would be a chronic lung infection model that developed
over several months; however, such a model is not readily
available (14). Nonetheless, in each model, the SCC1 aerosol
decreased the lung bacterial burden, indicating that it had a
beneficial antibacterial effect. Furthermore, survival in the
SCC1-treated groups in both models appeared to be linked to
averting bacteremia, as indicated by the striking difference in
the number of animals in each treatment group in which bacteria disseminated to the spleen. The results obtained with the
two infection models differed. The biochemical parameters of
inflammation did not correlate with the attenuated inflammation seen in the SCC1-treated animals in the acute infection
model, whereas they correlated directly with the decreased
inflammation of the lungs of the SCC1-treated animals in the
agarose bead model. One possible explanation is that the initial inoculum is necessarily lower in the agarose bead model
than the acute infection model and may consequently evoke a
different time course of inflammation.
Our report on the use of aerosolized silver as an antimicrobial for pulmonary infections joins a recent resurgence in interest in silver compounds that includes the development of
several different preparations for topical use, some of which
incorporate nanocrystalline silver (5, 10). This report is the first
to investigate the direct nebulization of a silver carbene complex in solution as a potential therapy for pulmonary infections. Given that SCC1 appears to be safe and effective in these
animal models of lung infection, further studies of SCC1 and
other silver carbene compounds, either directly aerosolized in
solution or in a nanoparticle suspension (17), appear to be
warranted. Nebulized silver-based antimicrobials may serve as
useful adjuncts to the current therapies for difficult-to-treat
pulmonary infections.
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was 6 g/ml (MIC range, 1 to 10 g/ml; the MIC90 is the
concentration at which 90% of the strains tested fail to grow)
(20). Other silver carbene complexes have demonstrated exceptional and comparable broad-spectrum activity against both
gram-positive and gram-negative bacteria; fungi; methicillinresistant S. aureus; and the biosafety level 3 bacteria Burkholderia pseudomallei, Burkholderia mallei, Bacillus anthracis, and
Yersinia pestis (16, 17, 28, 29, 31, 33). In particular, the MIC of
SCC1 for the mucoid clinical strain of P. aeruginosa studied
here, strain PA M57-15, is 2 g/ml. This strain had previously
been well studied in a mouse model of airway infection (36).
Prior to the in vivo studies, the in vitro cytotoxicity of SCC1
was investigated. Concentrations of SCC1 encompassing the
MIC90 noted in previous studies were applied to primary cultures of mTECs without apparent toxicity. While these cell
cytotoxicity studies could be supplemented with the investigation of biochemical markers of cell injury, the absence of cell
death with the use of concentrations below 200 g SCC1/ml
was notable, particularly because the 24-h direct incubation
period was likely greater than that which the respiratory epithelium would encounter in vivo. Moreover, the previously
reported microarray analysis of SCC1- and water-treated
mTECs showed minimal differences in gene expression after
24 h (20). These findings together suggested that the concentrations of SCC1 that would be required for bacterial growth
inhibition were not toxic to airway epithelial cells, and in vivo
studies seemed warranted.
Initial in vivo studies were aimed at investigating the potential toxicity of SCC1 delivered to the airways. To deliver SCC1,
a micropump nebulizer, which could provide particles capable
of delivery to the alveoli (⬍5 m), was used to provide a static
exposure over 5 min two times daily for 5 days (26). The
precise amount of silver that was delivered to the lung in these
treatment models has yet to be determined, in part because the
amount appears to be very low. The immediate harvesting of
the lungs after a single dose or after the last of multiple doses
followed by homogenization and attempted quantification of
Ag(I) by mass spectroscopy failed to demonstrate a signal
greater than that found in the lungs of the water-treated control animals (data not shown). It is possible, however, that
SCC1 was also delivered orally, because the animals ingested
compound that had been deposited by aerosol on their fur
through grooming. Although an initial aversion response to the
aerosolized SCC1 was noted, our investigations revealed that
this was most likely due to the caffeine derivative carrier rather
than the silver moiety.
The toxicology of silver has been remarkably understudied,
likely because silver causes so few clinically significant problems. At the cellular level, silver salts inhibit the proliferation
of some cell types, including lymphocytes and keratinocytes
(12, 18). Silver has been described to stimulate the respiratory
burst in neutrophils (19), which may enhance bacterial clearance but which could also increase inflammation (9). Suggested mechanisms of silver cytotoxicity include the inhibition
of cellular respiration with a loss of ATP (15). Other studies
showed that silver had no cytotoxic effects (1, 6). Consequently,
the safety of silver-based antimicrobials is still an open question. The studies of the cytotoxicity of SCC1 reported here
begin to address this question. Given the broad therapeutic
window between the MIC90 found for respiratory pathogens, 6
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